P. Kocsis

发表

Recent advancements in anti-migraine drug research: focus on attempts to decrease neuronal hyperexcitability.

Bence Farkas, Pál Kocsis, István Tarnawa, 2009, Recent patents on CNS drug discovery.

Blockers of voltage-gated sodium channels for the treatment of central nervous system diseases.

H. Bölcskei, P. Kocsis, I. Tarnawa, 2007, Recent patents on CNS drug discovery.

Scopolamine provocation-based pharmacological MRI model for testing procognitive agents

Szabolcs David, K. Tihanyi, P. Kocsis, 2015, Journal of psychopharmacology.

Effect of tolperisone on the resting brain and on evoked responses, an phMRI BOLD study

K. Tihanyi, P. Kocsis, Dávid Gajári, 2013, Brain Research Bulletin.

Simple pharmacological test battery to assess efficacy and side effect profile of centrally acting muscle relaxant drugs.

E. Kárpáti, P. Kocsis, I. Tarnawa, 2005, Journal of pharmacological and toxicological methods.

Effect of glutamate receptor antagonists on excitatory postsynaptic potentials in striatum

P. Kocsis, I. Tarnawa, I. Világi, 1998, Brain Research Bulletin.

Vascular Action as the Primary Mechanism of Cognitive Effects of Cholinergic, CNS-Acting Drugs, a Rat phMRI BOLD Study

János Éles, Pál Kocsis, Szabolcs David, 2014, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

Estradiol and isotype-selective estrogen receptor agonists modulate the mesocortical dopaminergic system in gonadectomized female rats

Z. Liposits, M. Sárvári, C. Vastagh, 2014, Brain Research.

Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy

Levente Kovács, Johanna Sápi, Zoltán Sápi, 2015, PloS one.

The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders.

P Kocsis, D. Comings, G. Dietz, 1991, JAMA.

Participation of AMPA- and NMDA-type excitatory amino acid receptors in the spinal reflex transmission, in rat

P. Kocsis, I. Tarnawa, S. Farkas, 2003, Brain Research Bulletin.

Voltage-gated sodium channel blockers, 2001-2006: An overview

Pál Kocsis, István Tarnawa, H. Bölcskei, 2008, Medicinal Chemistry Research.

Tolperisone-Type Drugs Inhibit Spinal Reflexes via Blockade of Voltage-Gated Sodium and Calcium Channels

A. Gere, P. Kocsis, I. Tarnawa, 2005, Journal of Pharmacology and Experimental Therapeutics.

Studies on the mechanism of action of RGH-5002, a centrally acting muscle relaxant, using whole cell patch clamp technique.

P. Kocsis, S. Farkas, N. Bielik, 1997, Neurobiology.

NR2B containing NMDA receptor dependent windup of single spinal neurons

P. Kocsis, I. Tarnawa, S. Farkas, 2004, Neuropharmacology.

Concerted action of antiepileptic and antidepressant agents to depress spinal neurotransmission: Possible use in the therapy of spasticity and chronic pain

K. Tihanyi, B. Farkas, P. Kocsis, 2007, Neurochemistry International.

NR2B receptors are involved in the mediation of spinal segmental reflex potentials but not in the cumulative motoneuronal depolarization in vitro

Gyula Kovács, Csilla Horváth, Pál Kocsis, 2004, Brain Research Bulletin.

Ghrelin Modulates the fMRI BOLD Response of Homeostatic and Hedonic Brain Centers Regulating Energy Balance in the Rat

Szabolcs David, M. Sárvári, K. Tihanyi, 2014, PloS one.

Comparative characterisation of the centrally acting muscle relaxant RGH-5002 and tolperisone and of lidocaine based on their effects on rat spinal cord in vitro.

P. Kocsis, S. Farkas, N. Bielik, 1997, Neurobiology.

[Mydeton: a centrally acting muscle relaxant drug from Gedeon Richter LTD].

P. Kocsis, I. Tarnawa, S. Farkas, 2002, Acta pharmaceutica Hungarica.